Wednesday, July 18, 2018 The results of the Canadian Cancer Trials Group (CCTG) BL.12 phase II randomized trial were presented at ASCO 2018 by Dr. Srikala Sridhar, the BL.12 Study Chair. In this interview Dr. Sridhar discusses the BL.12 study and what is next for bladder cancer clinical trial research. Bladder cancer is the 5th most common cancer in Canada with 9000 new cases annually. For patients with advanced disease who progress on first line chemotherapy, options include immunotherapy or taxane-based chemotherapy. Canadian Cancer Trials Group led a multicentre, international trial comparing Nab-P (nab-paclitaxel) 260mg/m2 IV q21 days to P (paclitaxel) 175mg/m2 IV q21 days in patients with advanced urothelial cancer progressing after one line of platinum-based therapy. The primary endpoint was progression free survival (PFS); secondary endpoints included overall survival (OS), response rate (RR), adverse events (AEs) using CTC AE V4.03 and QOL (EORTC-C15-PAL, FACT-Taxane). This investigator-initiated study was completed in collaboration with the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Find out more.
